NEWS

Roche’s Chest Pain Triage Algorithm Secures European CE Mark to Detect Acute Coronary Syndrome (ACS)

Shots: Roche has received the CE mark for its new Chest Pain Triage algorithm, developed with Universitätsklinikum Heidelberg as part of the navify algorithm suite to detect ACS in pts with chest pains; available in the EU, Middle East & Asia, with US availability planned for a later date Algorithm identifies non-cardiac chest pain by…

April 24, 2025

Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease

Shots: Repertoire & Genentech have entered into a collaboration & license agreement to identify & develop novel T cell-targeted therapies for an autoimmune disease, leveraging Repertoire’s DECODE platform As per the deal, Genentech will handle preclinical & clinical development along with global marketing in exchange for $35M upfront & ~$730M in development, regulatory & commercial…

April 24, 2025

Aclaris Therapeutics Reports the US FDA’s IND Clearance of ATI-052 for Immuno-Inflammatory Diseases

Shots: The US FDA has granted IND clearance to ATI-052 for the initiation of P-Ia/Ib trial The P-Ia/Ib trial assessing single & multiple ascending doses of ATI-052 followed by PoC portion in an undisclosed indication, is expected to begin in Q2’25 ATI-052 blocks upstream TSLP receptor signaling & downstream IL-4/IL-13 activation to inhibit a central…

April 24, 2025

Ipsen Reports P-II (ELMWOOD) Trial Data of Elafibranor for Primary Sclerosing Cholangitis (PSC)

Shots: Ipsen has reported P-II (ELMWOOD) trial data assessing elafibranor (80 or 120mg) vs PBO in 68 PSC pts for 12wks.; 96wks. OLE study evaluating elafibranor (120mg) is ongoing Trial demonstrated favorable safety & tolerability (1EP) at Wk. 12, with elafibranor 80 or 120mg vs PBO showing TRAEs 68.2%, 78.3% vs 69.6% pts, respectively Elafibranor…

April 24, 2025

Sebela Pharmaceuticals Reports Topline P-III (TRIUMpH) Program Data of Tegoprazan for Gastroesophageal Reflux Disease (GERD)

Shots: TRIUMpH program consists of 2 P-III trials assessing tegoprazan in US GERD pts with erosive esophagitis (EE) & non-erosive reflux disease (NERD); EE’s maintenance phase to end by Q3’25, with FDA’s NDA filing for both EE & NERD planned in Q4’25 EE study (vs lansoprazole) in 1250 pts (incl. 463 with LA Grade C/D)…

April 24, 2025

Mosaic Therapeutics In-Licenses ASTX029 & ASTX295 from Astex Pharmaceuticals for Combination Therapy Development for Oncology

Shots: Mosaic has in-licensed ASTX029 & ASTX295 from Astex (Otsuka Pharmaceutical’s subsidiary) to develop combination therapies using these assets, with the 1st combination study expected to begin in 2026 As per the deal, Astex granted Mosaic exclusive rights to develop combination products for pts with limited therapy options, receiving a 19% equity stake upfront &…

April 24, 2025

Merck’s Keytruda Regimen Receives Health Canada’s Approval for Malignant Pleural Mesothelioma (MPM)

Shots: Health Canada has approved Keytruda + pemetrexed + Pt-based CT as 1L treatment of unresectable advanced or metastatic MPM based on P-II/III (IND.227/KEYNOTE-483) trial led by CCTG in collaboration with NCIN & IFCT Trial assessed the regimen in MPM pts (n=440) who received either Keytruda (200mg, IV) + pemetrexed (500mg/m^2) & Pt-based CT on Day…

April 23, 2025

Boehringer Ingelheim Enters a ~$573M Deal with Tessellate Bio to Develop Novel Therapies for ALT-positive tumors

Shots: BI & Tessellate Bio have entered into a research collaboration & global license agreement to develop oral therapies for ALT-positive tumors As per the terms, Tessellate Bio will receive near term payments incl. an upfront license fee, research funding & technical milestones along with downstream success-based milestones, making it an aggregate of ~$573M (~€500M)…

April 23, 2025

VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies

Shots: VERAXA to reverse merge with Voyager, where the combined entity- "VERAXA Biotech” will be listed on Nasdaq under VERX ticker; closing expected in Q4’25 As per the deal, VERAXA will have access to ~$253M cash from Voyager’s trust at closing & contribute ~$1.3B in equity for ~130M shares, with all shareholders rolling over 100%…

April 23, 2025

Veravas Launches VeraBIND Tau to Detect Alzheimer’s Disease & other Tauopathies

Shots: Veravas has launched VeraBIND Tau to detect both symptomatic & pre-symptomatic pts with Alzheimer's disease (AD) or other tau-related neurodegenerative disorders (tauopathies) In an analytical verification study, VeraBIND Tau showed 96% sensitivity, 90% specificity, & 92% agreement with tau PET imaging, detecting Alzheimer’s-related tau & offering VeraBIND Tau score, a semi-quantitative measure of pathologically…

April 23, 2025

NEWS

Roche’s Chest Pain Triage Algorithm Secures European CE Mark to Detect Acute Coronary Syndrome (ACS)

Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease

Aclaris Therapeutics Reports the US FDA’s IND Clearance of ATI-052 for Immuno-Inflammatory Diseases

Ipsen Reports P-II (ELMWOOD) Trial Data of Elafibranor for Primary Sclerosing Cholangitis (PSC)

Sebela Pharmaceuticals Reports Topline P-III (TRIUMpH) Program Data of Tegoprazan for Gastroesophageal Reflux Disease (GERD)

Mosaic Therapeutics In-Licenses ASTX029 & ASTX295 from Astex Pharmaceuticals for Combination Therapy Development for Oncology

Merck’s Keytruda Regimen Receives Health Canada’s Approval for Malignant Pleural Mesothelioma (MPM)

Boehringer Ingelheim Enters a ~$573M Deal with Tessellate Bio to Develop Novel Therapies for ALT-positive tumors

VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies

Veravas Launches VeraBIND Tau to Detect Alzheimer’s Disease & other Tauopathies

Contact US

FOLLOW US